Literature DB >> 11164417

Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.

E Isusi1, P Aspichueta, M Liza, M L Hernández, C Díaz, G Hernández, M J Martínez, B Ochoa.   

Abstract

The short- and long-term in vitro effects of the hydroxymethylglutaryl-CoA reductase inhibitor atorvastatin, compared with lovastatin and simvastatin on VLDL secretion, and on the formation and the neutral and acid lysosomal hydrolysis of cholesteryl esters was investigated in rat liver hepatocytes maintained in suspension (2 or 4 h) or cultured in monolayers (24 h). All statins time-dependently reduced [14C]oleate incorporation into cholesteryl esters, but when exogenous cholesterol was added only atorvastatin caused an immediate transient decrease in hepatocyte ACAT activity. Activity of the lysosomal, microsomal and cytosolic CEH isoforms was unaffected by the hepatocyte treatments. Statins reduced free and esterified cholesterol mass in hepatocyte microsomes after 2 h, and this was followed by a modest decline in VLDL cholesteryl esters, whilst secretion of VLDL apoB and triglycerides was unaltered. However, after 24 h of treatment, statins caused generalized 20-40% decreases in the secretion of VLDL apoB, cholesterol and triglycerides, with the reduction in apoB48 secretion being significantly superior to that caused in apoB100. The mean diameter of secreted VLDL was not modified by either duration or drug treatment. Additional studies with subcellular fractions demonstrated that statins have a direct selective effect on the enzymes governing the cholesterol-cholesteryl ester cycle, with the exception of the microsomal CEH. Atorvastatin, lovastatin and simvastatin inhibited ACAT activity in microsomes by 50% at doses of 250, 100 and 50 microM, respectively. The cytosolic CEH elicited a biphasic profile of activity with activations up to 100 microM statin and inhibitions above 250 microM, and the lysosomal CEH was only inhibited by atorvastatin at a dose of 100 microM or more. We conclude that a prolonged, but not a short, limited availability of hepatocyte cholesterol derived from the endogenous synthesis reduces VLDL secretion, and that reactivity of statins at the cellular level are more similar than reactivity at the subcellular level as regards the cholesterol-cholesteryl ester cycle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11164417     DOI: 10.1016/s0021-9150(00)00407-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

1.  Comparison of the effects of dietary n-3 and n-6 polyunsaturated fatty acids on very-low-density lipoprotein secretion when delivered to hepatocytes in chylomicron remnants.

Authors:  X Zheng; M Avella; K M Botham
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

2.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Authors:  Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

3.  Dual action of neutral sphingomyelinase on rat hepatocytes: activation of cholesteryl ester metabolism and biliary cholesterol secretion and inhibition of VLDL secretion.

Authors:  Mariana Liza; Yolanda Chico; Olatz Fresnedo; Begoña Ochoa
Journal:  Lipids       Date:  2003-01       Impact factor: 1.880

4.  Lipid analysis reveals quiescent and regenerating liver-specific populations of lipid droplets.

Authors:  Itsaso García-Arcos; Paola González-Kother; Patricia Aspichueta; Yuri Rueda; Begoña Ochoa; Olatz Fresnedo
Journal:  Lipids       Date:  2010-11-10       Impact factor: 1.880

5.  Differential modulation of prostaglandin receptor mRNA abundance by prostaglandins in primary cultured rat hepatocytes.

Authors:  Silvia Pérez; Eduardo N Maldonado; Patricia Aspichueta; Begoña Ochoa; Yolanda Chico
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

6.  Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.

Authors:  Paul N Hopkins; M Nazeem Nanjee; Lily L Wu; Michael G McGinty; Eliot A Brinton; Steven C Hunt; Jeffrey L Anderson
Journal:  Atherosclerosis       Date:  2009-05-22       Impact factor: 5.162

7.  Influence of the fatty acid composition of lipids in chylomicron remnants derived from fish or corn oil on the lipid profile of cultured rat hepatocytes.

Authors:  E N Maldonado; Y Chico; K M Botham; M I Aveldaño; B Ochoa
Journal:  J Physiol Biochem       Date:  2003-06       Impact factor: 4.158

8.  Association of Circulating Cathepsin S and Cardiovascular Disease Among Patients With Type 2 Diabetes: A Cross-Sectional Community-Based Study.

Authors:  Yu Jing; Jie Shi; Bin Lu; Weiwei Zhang; Yehong Yang; Jie Wen; Renming Hu; Zhen Yang; Xuanchun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-05       Impact factor: 5.555

9.  Differential influence of different dietary fatty acids on very low-density lipoprotein secretion when delivered to hepatocytes in chylomicron remnants.

Authors:  Iliana López-Soldado; Michael Avella; Kathleen M Botham
Journal:  Metabolism       Date:  2009-02       Impact factor: 8.694

10.  Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2.

Authors:  Marlen Martinez-Gutierrez; Luis A Correa-Londoño; Jaime E Castellanos; Juan C Gallego-Gómez; Jorge E Osorio
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.